Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment
出版年份 2016 全文链接
标题
Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment
作者
关键词
-
出版物
CTS-Clinical and Translational Science
Volume 9, Issue 3, Pages 139-148
出版商
Wiley
发表日期
2016-05-12
DOI
10.1111/cts.12397
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus
- (2016) Melanie Thompson et al. AIDS
- Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver Disease
- (2016) Sahil Mittal et al. Clinical Gastroenterology and Hepatology
- Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design
- (2016) Scott Friedman et al. Contemporary Clinical Trials
- Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
- (2015) Robert J. Wong et al. GASTROENTEROLOGY
- Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
- (2015) Paul Angulo et al. GASTROENTEROLOGY
- O033 : CCR2+ infiltrating monocytes promote acetaminophen-induced acute liver injury – therapeutic implications of inhibiting CCR2 and CCL2
- (2015) O. Krenkel et al. JOURNAL OF HEPATOLOGY
- Current efforts and trends in the treatment of NASH
- (2015) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Persistent Immune Activation and Carotid Atherosclerosis in HIV-Infected Ugandans Receiving Antiretroviral Therapy
- (2015) Mark J. Siedner et al. JOURNAL OF INFECTIOUS DISEASES
- Over-activation of TLR5 signaling by high-dose flagellin induces liver injury in mice
- (2014) Yang Xiao et al. Cellular & Molecular Immunology
- Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice
- (2013) Jean-Philippe Pradere et al. HEPATOLOGY
- Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.
- (2013) Robert J. Wong et al. HEPATOLOGY
- Pathological bacterial translocation in liver cirrhosis
- (2013) Reiner Wiest et al. JOURNAL OF HEPATOLOGY
- From NAFLD to NASH to cirrhosis—new insights into disease mechanisms
- (2013) Alexander Wree et al. Nature Reviews Gastroenterology & Hepatology
- The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology and the American Gastroenterological Association
- (2012) Naga Chalasani et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2
- (2012) Kouichi Miura et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults
- (2011) G. Vernon et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Contrasting Roles for TLR Ligands in HIV-1 Pathogenesis
- (2010) Beda Brichacek et al. PLoS One
- Hepatic recruitment of the inflammatory Gr1+monocyte subset upon liver injury promotes hepatic fibrosis
- (2009) Karlin Raja Karlmark et al. HEPATOLOGY
- CCR2 promotes hepatic fibrosis in mice
- (2009) Ekihiro Seki et al. HEPATOLOGY
- Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction
- (2008) Roger K. Verbeeck EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started